Past 12-month and lifetime comorbidity and poly-drug use of ecstasy users among young adults in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions

Drug and Alcohol Dependence

Volumn 97, Issue 1-2, 2008, Pages 139-149

  Keyes, Katherine M ^a,b   Martins, Silvia S ^c   Hasin, Deborah S ^a,b,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^d NONE   (United States)

Author keywords

Ecstasy; Epidemiology; MDMA; Poly drug; Young adult

Indexed keywords

ALCOHOL; ECSTASY; ILLICIT DRUG;

ADULT; ALCOHOL ABUSE; ALCOHOLISM; ANXIETY DISORDER; ARTICLE; COMORBIDITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG DEPENDENCE; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; LIFESPAN; MALE; MOOD DISORDER; PANIC; PERSONALITY DISORDER; PHOBIA; PREVALENCE; PRIORITY JOURNAL; UNITED STATES;

ADOLESCENT; ADULT; AGE FACTORS; ALCOHOLISM; AMPHETAMINE-RELATED DISORDERS; COMORBIDITY; DIAGNOSIS, DUAL (PSYCHIATRY); FAMILY; FEMALE; HUMANS; MALE; MENTAL DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PSYCHIATRIC STATUS RATING SCALES; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED STATES; YOUNG ADULT;

EID: 46649092291     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drugalcdep.2008.04.001     Document Type: Article

References (62)

1. Agrawal A., Edenberg H.J., Foroud T., Bierut L.J., Dunne G., Hinrichs A.L., Nurnberger J.I., Crowe R., Kuperman S., Schuckit M.A., Begleiter H., Porjesz B., and Dick D.M. Association of GABRA2 with drug dependence in the collaborative study of the genetics of alcoholism sample. Behav. Genet. 36 (2005) 640-650
2. American Psychiatric Association, 1994. Fourth Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Association, Washington, DC.
3. Burgess C., O'Donohoe A., and Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. Eur. Psychiatry 15 (2000) 287-294
4. Carmo H., Brulport M., Hermes M., Oesch F., Silva R., Ferreira L.M., Branco P.S., Boer D., Remiao F., Felix C., Schon M.R., Krebsfaenger N., Doehmer J., Bastos M., and Hengstler J.G. Influence of CYP2D6 polymorphisms on 3,4-methylenedioxymethamphetamine ('ecstasy') cytotoxicity. Pharmacogenet. Genom. 16 (2006) 789-799
5. Chou S.P., Dawson D.A., Stinson F.S., Huang B., Pickering S.P., Zhou Y., and Grant B.F. The prevalence of drinking and driving in the United States, 2001-2002: results from the National Epidemiological Survey on Alcohol and Related Conditions. Drug Alcohol Depend. 83 (2006) 137-146
6. Clemens K.J., Cornish J.L., Hunt G.E., and McGregor I.S. Repeated weekly exposure to MDMA, methamphetamine or their combination: long-term behavioural and neurochemical effects in rats. Drug Alcohol Depend. 86 (2007) 183-190
7. Clemens K.J., Cornish J.L., Li K.M., Hunt G.E., and McGregor I.S. MDMA ('ecstasy') and methamphetamine combined: order of administration influences hyperthermic and long-term adverse effects in female rats. Neuropharmacology 49 (2005) 195-207
8. Compton W.M., Conway K.P., Stinson F.S., Colliver J.D., and Grant B.F. Prevalence, correlates, and comorbidity of DSM-IV antisocial personality syndromes and alcohol and specific drug use disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 66 (2005) 676-685
9. Compton W.M., Cottler L.B., Jacobs J.L., Ben-Abdallah A., and Spitznagel E.L. The role of psychiatric disorder in predicting drug dependence treatment outcomes. Am. J. Psychiatry 160 (2003) 890-895
10. Daumann J., Schnitker R., Weidemann J., Schnell K., Thron A., and Gouzoulis-Mayfrank E. Psychological profile of abstinent recreational ecstasy (MDMA) users and significance of concomitant cannabis use. Hum. Psychopharmacol. 16 (2001) 627-633
11. Dawson D.A., Grant B.F., Stinson F.S., Chou P.S., Huang B., and Ruan W.J. Recovery from DSM-IV alcohol dependence: United States, 2001-2002. Addiction 100 (2005) 281-292
12. Degenhardt L., Barker B., and Topp L. Patterns of ecstasy use in Australia: findings from a National Household Survey. Addiction 99 (2004) 187-193
13. Degenhardt L., Coffey C., Moran P., Carlin J.B., and Patton G.C. The predictors and consequences of adolescent amphetamine use: findings from the Victoria Adolescent Health Cohort Study. Addiction 102 (2007) 1076-1084
14. De la Torre R., Farre M., Mathuna B.O., Roset P.N., Pizarro N., Segura M., Torrens M., Ortuno J., Pujadas M., and Cami J. MDMA (ecstasy) pharmacokinetics in a NYP2D6 poor metaboliser and in nine CYP2D6 extensive metabolisers. Eur. J. Clin. Pharmacol. 61 (2005) 551-554
15. De Win M.M., Reneman L., Reitsma J.B., den heeten G.J., Booij J., and van den Brink W. Mood disorders and serotonin transporter density in ecstasy users-the influence of long-term abstention, dose, and gender. Psychopharmacology 173 (2004) 376-382
16. Downing J. The psychological and physiological effects of MDMA in normal volunteers. J. Psychoactive Drugs 18 (1986) 335-339
17. Dumont G.J.H., and Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetmine in healthy volunteers. J. Psychoparmacol. 20 (2006) 176-187
18. Fendrich M., Wislar J.S., Johnson T.P., and Hubbell A. A contextual profile of club drug use among adults in Chicago. Addiction 98 (2003) 1693-1703
19. Galaif E.R., and Newcomb M.D. Predictors of polydrug use among four ethnic groups: a 12-year longitudinal study. Addict. Behav. 24 (1999) 607-631
20. Gerra G., Zaimovic A., Ferri M., Zambelli U., Timpano M., and Neri E. Long-lasting effects of (+/-)3,4-methylenedioxymetamphetamine (ecstasy) on serotonin system function in humans. Biol. Psychiatry 47 (2000) 127-136
21. Gouzoulis-Mayfrank E., and Daumann J. The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J. Psychopharmacol. 20 (2006) 188-193
22. Grant, B.F., Dawson, D.A., Hasin, D.S., 2001. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-DSM-IV version (AUDADIS-IV). National Institute on Alcohol Abuse and Alcoholism. Available at http://niaaa.census.gov/ (accessed on December 1, 2007).
23. Grant B.F., Dawson D.A., Stinson F.S., Chou P.S., Kay W., and Pickering R. The Alcohol Use Disorder and Associated Disabilities Interview Schedule-IV (AUDADIS-IV): reliability of alcohol consumption, tobacco use, family history of depression and psychiatric diagnostic modules in a general population sample. Drug Alcohol Depend. 71 (2003) 7-16
24. Grant B.F., Harford T.C., Dawson D.A., Chou P., and Pickering R. The Alcohol Use Disorder and Associated Disabilities Schedule: reliability of alcohol and drug modules in a general population sample. Drug Alcohol Depend. 39 (1995) 37-44
25. Grant B.F., Hasin D.S., Stinson F.S., Dawson D.A., Chou S.P., Ruan W.J., and Pickering R.P. Prevalence, correlates, and disability of personality disorders in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry 65 (2004) 948-958
26. Grant B.F., Hasin D.S., Stinson F.S., Dawson D.A., Chou S.P., Ruan W.J., and Huang B. Co-occurrence of 12-month mood and anxiety disorders and personality disorders in the US: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Psychiatr. Res. 39 (2005) 1-9
27. Grant, B.F., Moore, T.C., Shepard, J., Kaplan, K., 2003a. Source and Accuracy Statement for Wave 1 of the 2001-2002 National Epidemiologic Survey on Alcohol and Related Conditions. National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD. Available at http://niaaa.census.gov/pdfs/source_and_accuracy_statement.pdf (accessed December 1, 2007).
28. Grant B.F., Stinson F.S., Dawson D.A., Chou S.P., Dufour M.C., Compton W., Pickering R.P., and Kaplan K. Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 61 (2004) 807-816
29. Gross S.R., Barrett S.P., Shestowsky J.S., and Pihl R.O. Ecstasy and drug consumption patterns: a Canadian rave population study. Can. J. Psychiatry 47 (2002) 546-551
30. Hasin D., Carpenter K.M., McCloud S., Smith M., and Grant B.F. The Alcohol Use Disorder and Associated Disabilities Interview Schedule (AUDADIS): reliability of alcohol and drug modules in a clinical sample. Drug Alcohol Depend. 44 (1997) 133-141
31. Hasin D.S., Goodwin R.D., Stinson F.S., and Grant B.F. The epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 62 (2005) 1097-1106
32. Hasin D.S., Stinson F.S., Ogburn E., and Grant B.F. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry 97 (2007) 830-842
33. Hernandez-Lopez C., Farre M., Roset P., Menoyo E., Pizarro N., Ortuno J., Torrens M., Cami J., and de La Torre R. 3,4-Methylenedioxymethamphetamine (ecstasy) and alcohol interactions in humans: psychomotor performance, subjective effects, and pharmacokinetics. J. Pharmacol. Exp. Ther. 300 (2002) 235-244
34. Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2007a. Monitoring the Future National Survey Results on Drug Use, 1975-2006. Volume I: Secondary School Students. NIH Publication No. 07-6205. National Institute on Drug Abuse, Bethesda, MD, 699 pp.
35. Johnston, L.D., O'Malley, P.M., Bachman, J.G., Schulenberg, J.E., 2007b. Monitoring the Future National Results on Adolescent Drug Use: Overview of Key Findings, 2006. NIH Publication No. 07-6202. National Institute on Drug Abuse, Bethesda, MD, 71 pp.
36. Kendler K.S., Prescott C.A., Myers J., and Neale M.C. The structure of genetic and environmental risk factors for common psychiatric and substance use disorders in men and women. Arch. Gen. Psychiatry 60 (2003) 929-937
37. Klitzman R.L., Greenberg J.D., Pollack L.M., and Dolezal C. MDMA ('ecstasy') use, and its association with high risk behaviors, mental health, and other factors among gay/bisexual men in New York City. Drug Alcohol Depend. 66 (2002) 115-125
38. Landry M.J. MDMA: a review of epidemiologic data. J. Psychoactive Drugs 34 (2002) 163-169
39. Lieb R., Schuetz C.G., Pfister H., von Sydow K., and Wittchen H. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend. 68 (2002) 195-207
40. Liechti M.E., Kunz I., and Kupferschmidt H. Acute medial problsm due to ecstasy use. Case-series of emergency department visits. Swiss Med. Weekly 135 (2005) 652-657
41. Lynch T., and Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am. Fam. Physician 76 (2007) 391-395
42. MacInnes N., Handley S.L., and Harding G.F.A. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J. Psychopharmacol. 15 (2001) 181-186
43. Martins S.S., Mazzotti G., and Chilcoat H.D. Trends in ecstasy use in the United States from 1995 to 2001: comparison with marijuana users and association with other drug use. Exp. Clin. Psychopharmacol. 13 (2005) 244-252
44. Parrott A.C. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, dosage levels, and the changing perceptions of purity. Psychopharmacology 173 (2004) 234-241
45. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J. Psychopharmacol. 20 (2006) 147-163
46. Parrott A.C., Gouzoulis-Mayfrank E., Rodgers J., and Solowij N. Ecstasy/MDMA and cannabis: the complexities of their interactive neuropsychobiological effect. J. Psychopharmacol. 18 (2004) 572-575
47. Research Triangle Institute, 2004. Software for Survey Data Analysis (SUDAAN), Version 9.0. Research Triangle Institute, Research Triangle Park, NC.
48. Schifano F., Di Furia L., Forza G., Minicuci N., and Bricolo R. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend. 52 (1998) 85-90
49. Scholey A.B., Parrott A.C., Buchanan T., Heffernan T., Ling J., and Rodgers J. Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a www study. Addict. Behav. 29 (2004) 743-752
50. Spruit I.P. Monitoring synthetic drug markets, trends and public health. Subst. Use Misuse 36 (2001) 23-47
51. Substance Abuse and Mental Health Services Administration, 2002. Emergency Department Trends from Drug Abuse Warning Network, Final Estimates: 1995-2002. DHHS Publication No. SMA 03-3780. DAWN Series D-24. Rockville, MD.
52. Substance Abuse and Mental Health Services Administration, Office of Applied Studies, 2004. Nonmedical Use of Prescription Pain Relievers. The NSDUH Report. Available at http://www.oas.samhsa.gov/2k4/pain/pain.cfm (accessed December 1, 2007).
53. Thomasius R., Petersen K.U., Buchert R., Andresen B., Zapletalova P., and Wartberg L. Mood, cognition, and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology 167 (2003) 85-96
54. Thomasius R., Petersen K.U., Zapletalova P., Wartberg L., Zeichner D., and Schmoldt A. Mental disorders in current and former heavy ecstasy (MDMA) users. Addiction 100 (2005) 1310-1319
55. Thomasius R., Zapletalova R., Petersen K., Buchert R., Andersen B., Wartberg L., Nebeling B., and Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J. Psychopharmacol. 20 (2006) 211-225
56. Topp L., Hando J., Dillon P., Roche A., and Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend. 55 (1999) 105-115
57. Verheyden S.L., Henry J.A., and Curran H.V. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum. Psychopharmacol. 18 (2003) 507-517
58. Verheyden S.L., Maidment R., and Curran H.V. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J. Psychopharmacol. 17 (2003) 371-378
59. von Sydow K., Lieb R., Pfister H., Hofler M., and Wittchen H.U. Use, abuse, and dependence of ecstasy and related drugs in adolescents and young adults: a transient phenomenon? Results from a longitudinal community study. Drug Alcohol Depend. 66 (2002) 147-159
60. Wu L.T., Schlenger W.E., and Galvin D.M. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths. Drug Alcohol Depend. 84 (2006) 102-113
61. Yang J., Jamei M., Heydari A., Yeo K.R., de la Torre R., Farre M., Tucker G.T., and Rostami-Hodjegan A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20 (2006) 842-849
62. Zacny J., Bigelow G., Compton P., Foley K., Iguchi M., and Sannerud C. College on Problems of Drug Dependence taskforce on prescription opioid non-medical use and abuse: position statement. Drug Alcohol Depend. 69 (2003) 215-232